Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNDZ) Gross Margin (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Gross Margin for 15 consecutive years, with 94.99% as the latest value for Q4 2025.

  • Quarterly Gross Margin rose 161.0% to 94.99% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 94.57% through Dec 2025, up 120.0% year-over-year, with the annual reading at 94.57% for FY2025, 120.0% up from the prior year.
  • Gross Margin hit 94.99% in Q4 2025 for Ligand Pharmaceuticals, down from 96.71% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 96.71% in Q3 2025 to a low of 57.1% in Q4 2022.
  • Historically, Gross Margin has averaged 85.75% across 5 years, with a median of 90.05% in 2023.
  • Biggest five-year swings in Gross Margin: plummeted -2165bps in 2022 and later surged 3706bps in 2023.
  • Year by year, Gross Margin stood at 78.75% in 2021, then fell by -27bps to 57.1% in 2022, then surged by 65bps to 94.16% in 2023, then decreased by -1bps to 93.37% in 2024, then grew by 2bps to 94.99% in 2025.
  • Business Quant data shows Gross Margin for LGNDZ at 94.99% in Q4 2025, 96.71% in Q3 2025, and 93.9% in Q2 2025.